AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP
AARP Inc. said Tuesday that U.S. trade negotiators should not push for a provision in the Trans-Pacific Partnership that would allow brand-name biologic drugs to have exclusive access to the market...To view the full article, register now.
Already a subscriber? Click here to view full article